The drug controller general of India, the DCGI, have started intensive investigative study of the type 2 diabetic medication, Rosiglitazone. The DCGI were prompted by American reports of a much increased risk of heart attack amongst diabetics taking the drug.
Healthcare staff and doctors around the world face uncertainty on account of the warnings. Glaxo, manufacturer of the controversial Avandia, have defended their product. Both Avandia and Actos (a similar drug created by Takeda Pharmacueticals) will now have to carry serious black box warnings. This will alert medical staff to the higher risk of congestive heart failure.
The type of heart failure that those taking rosiglitazone face an increased risk of occurs when the pumping of heart falters, and fluid accumulates throughout the body. The New England Journal of Medicine blew the doors open, by publishing a recent study putting risks of heart failure at 43 per cent. The DCGI will make their own decision on whether the medication remains suitable for prescription to Indian patients.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…